Do analysts recommend NCNA or QLGN?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NuCana 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Qualigen Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better valuation and earnings, NCNA or QLGN?

NuCana is trading at a lower price-to-earnings ratio than Qualigen Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio NuCana N/A N/A -$38.71M -$2.98 N/A Qualigen Therapeutics N/A N/A -$6.26M -$7.50 N/A

Is NCNA or QLGN more profitable?

Qualigen Therapeutics' return on equity of 0.00% beat NuCana's return on equity. Company Net Margins Return on Equity Return on Assets NuCana N/A -153.61% -116.03% Qualigen Therapeutics N/A N/A -202.16%

Do analysts prefer QLGN or MTEX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Qualigen Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Mannatech 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media refer more to QLGN or MTEX?

In the previous week, Mannatech had 2 more articles in the media than Qualigen Therapeutics. MarketBeat recorded 3 mentions for Mannatech and 1 mentions for Qualigen Therapeutics. Mannatech's average media sentiment score of 0.86 beat Qualigen Therapeutics' score of 0.00 indicating that Mannatech is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Qualigen Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Mannatech 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate QLGN or CELZ?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Qualigen Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Creative Medical Technology 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Is QLGN or CELZ more profitable?

Qualigen Therapeutics' return on equity of 0.00% beat Creative Medical Technology's return on equity. Company Net Margins Return on Equity Return on Assets Qualigen Therapeutics N/A N/A -202.16% Creative Medical Technology N/A -88.38% -84.71%

Do analysts rate BCLI or QLGN?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Brainstorm Cell Therapeutics 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Qualigen Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger valuation and earnings, BCLI or QLGN?

Brainstorm Cell Therapeutics is trading at a lower price-to-earnings ratio than Qualigen Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Brainstorm Cell Therapeutics N/A N/A -$11.62M -$1.64 N/A Qualigen Therapeutics N/A N/A -$6.26M -$7.50 N/A

Is BCLI or QLGN more profitable?

Company Net Margins Return on Equity Return on Assets Brainstorm Cell Therapeutics N/A N/A -519.50% Qualigen Therapeutics N/A N/A -202.16%

Does the media prefer BCLI or QLGN?

In the previous week, Brainstorm Cell Therapeutics had 3 more articles in the media than Qualigen Therapeutics. MarketBeat recorded 4 mentions for Brainstorm Cell Therapeutics and 1 mentions for Qualigen Therapeutics. Brainstorm Cell Therapeutics' average media sentiment score of 0.00 equaled Qualigen Therapeutics'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Brainstorm Cell Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Qualigen Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer OBSV or QLGN?

Given ObsEva's higher probable upside, analysts clearly believe ObsEva is more favorable than Qualigen Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ObsEva 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Qualigen Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger valuation & earnings, OBSV or QLGN?

Qualigen Therapeutics is trading at a lower price-to-earnings ratio than ObsEva, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio ObsEva N/A N/A -$58.38M -$0.92 N/A Qualigen Therapeutics N/A N/A -$6.26M -$7.50 N/A

Is OBSV or QLGN more profitable?

Qualigen Therapeutics' return on equity of 0.00% beat ObsEva's return on equity. Company Net Margins Return on Equity Return on Assets ObsEva N/A -416.36% -92.01% Qualigen Therapeutics N/A N/A -202.16%

Qualigen Therapeutics (QLGN) Competitors

$1.27 -0.01 (-0.78%)

As of 05/27/2026

Compare

QLGN vs. NCNA, MTEX, CELZ, BCLI, and OBSV

Should you buy Qualigen Therapeutics stock or one of its competitors? MarketBeat compares Qualigen Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Qualigen Therapeutics include NuCana (NCNA), Mannatech (MTEX), Creative Medical Technology (CELZ), Brainstorm Cell Therapeutics (BCLI), and ObsEva (OBSV). These companies are all part of the "pharmaceutical products" industry.

How does Qualigen Therapeutics compare to NuCana?

NuCana (NASDAQ:NCNA) and Qualigen Therapeutics (NASDAQ:QLGN) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their earnings, risk, valuation, profitability, dividends, analyst recommendations, media sentiment and institutional ownership.

In the previous week, NuCana and NuCana both had 1 articles in the media. NuCana's average media sentiment score of 1.89 beat Qualigen Therapeutics' score of 0.00 indicating that NuCana is being referred to more favorably in the media.

Company	Overall Sentiment
NuCana	Very Positive
Qualigen Therapeutics	Neutral

NuCana has a beta of 2.17, suggesting that its share price is 117% more volatile than the broader market. Comparatively, Qualigen Therapeutics has a beta of 0.24, suggesting that its share price is 76% less volatile than the broader market.

NuCana is trading at a lower price-to-earnings ratio than Qualigen Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NuCana	N/A	N/A	-$38.71M	-$2.98	N/A
Qualigen Therapeutics	N/A	N/A	-$6.26M	-$7.50	N/A

44.0% of NuCana shares are owned by institutional investors. Comparatively, 3.2% of Qualigen Therapeutics shares are owned by institutional investors. 31.2% of NuCana shares are owned by company insiders. Comparatively, 1.8% of Qualigen Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NuCana	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Qualigen Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Qualigen Therapeutics' return on equity of 0.00% beat NuCana's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NuCana	N/A	-153.61%	-116.03%
Qualigen Therapeutics	N/A	N/A	-202.16%

Summary

NuCana beats Qualigen Therapeutics on 6 of the 9 factors compared between the two stocks.

How does Qualigen Therapeutics compare to Mannatech?

Qualigen Therapeutics (NASDAQ:QLGN) and Mannatech (NASDAQ:MTEX) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, profitability, risk, earnings, media sentiment, valuation and institutional ownership.

Qualigen Therapeutics has a net margin of 0.00% compared to Mannatech's net margin of -11.97%. Qualigen Therapeutics' return on equity of 0.00% beat Mannatech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Qualigen Therapeutics	N/A	N/A	-202.16%
Mannatech	-11.97%	-2,383.34%	-40.24%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Qualigen Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Mannatech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Mannatech had 2 more articles in the media than Qualigen Therapeutics. MarketBeat recorded 3 mentions for Mannatech and 1 mentions for Qualigen Therapeutics. Mannatech's average media sentiment score of 0.86 beat Qualigen Therapeutics' score of 0.00 indicating that Mannatech is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Qualigen Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Mannatech	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

3.2% of Qualigen Therapeutics shares are held by institutional investors. Comparatively, 13.0% of Mannatech shares are held by institutional investors. 1.8% of Qualigen Therapeutics shares are held by company insiders. Comparatively, 41.5% of Mannatech shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Qualigen Therapeutics has a beta of 0.24, indicating that its share price is 76% less volatile than the broader market. Comparatively, Mannatech has a beta of 0.61, indicating that its share price is 39% less volatile than the broader market.

Qualigen Therapeutics has higher earnings, but lower revenue than Mannatech. Mannatech is trading at a lower price-to-earnings ratio than Qualigen Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Qualigen Therapeutics	N/A	N/A	-$6.26M	-$7.50	N/A
Mannatech	$108.04M	0.10	-$15.21M	-$6.71	N/A

Summary

Mannatech beats Qualigen Therapeutics on 8 of the 12 factors compared between the two stocks.

How does Qualigen Therapeutics compare to Creative Medical Technology?

Qualigen Therapeutics (NASDAQ:QLGN) and Creative Medical Technology (NASDAQ:CELZ) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, valuation, risk, media sentiment, profitability, dividends, earnings and analyst recommendations.

In the previous week, Qualigen Therapeutics and Qualigen Therapeutics both had 1 articles in the media. Creative Medical Technology's average media sentiment score of 1.90 beat Qualigen Therapeutics' score of 0.00 indicating that Creative Medical Technology is being referred to more favorably in the news media.

Company	Overall Sentiment
Qualigen Therapeutics	Neutral
Creative Medical Technology	Very Positive

Qualigen Therapeutics has a beta of 0.24, meaning that its share price is 76% less volatile than the broader market. Comparatively, Creative Medical Technology has a beta of 1.87, meaning that its share price is 87% more volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Qualigen Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Creative Medical Technology	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

3.2% of Qualigen Therapeutics shares are owned by institutional investors. Comparatively, 1.4% of Creative Medical Technology shares are owned by institutional investors. 1.8% of Qualigen Therapeutics shares are owned by insiders. Comparatively, 1.7% of Creative Medical Technology shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Creative Medical Technology has higher revenue and earnings than Qualigen Therapeutics. Creative Medical Technology is trading at a lower price-to-earnings ratio than Qualigen Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Qualigen Therapeutics	N/A	N/A	-$6.26M	-$7.50	N/A
Creative Medical Technology	$10K	825.47	-$5.99M	-$2.14	N/A

Qualigen Therapeutics' return on equity of 0.00% beat Creative Medical Technology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Qualigen Therapeutics	N/A	N/A	-202.16%
Creative Medical Technology	N/A	-88.38%	-84.71%

Summary

Creative Medical Technology beats Qualigen Therapeutics on 7 of the 11 factors compared between the two stocks.

How does Qualigen Therapeutics compare to Brainstorm Cell Therapeutics?

Brainstorm Cell Therapeutics (NASDAQ:BCLI) and Qualigen Therapeutics (NASDAQ:QLGN) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, earnings, media sentiment, valuation, institutional ownership, profitability, risk and analyst recommendations.

14.3% of Brainstorm Cell Therapeutics shares are held by institutional investors. Comparatively, 3.2% of Qualigen Therapeutics shares are held by institutional investors. 11.2% of Brainstorm Cell Therapeutics shares are held by insiders. Comparatively, 1.8% of Qualigen Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Brainstorm Cell Therapeutics has a beta of 0.22, suggesting that its share price is 78% less volatile than the broader market. Comparatively, Qualigen Therapeutics has a beta of 0.24, suggesting that its share price is 76% less volatile than the broader market.

Company	Net Margins	Return on Equity	Return on Assets
Brainstorm Cell Therapeutics	N/A	N/A	-519.50%
Qualigen Therapeutics	N/A	N/A	-202.16%

In the previous week, Brainstorm Cell Therapeutics had 3 more articles in the media than Qualigen Therapeutics. MarketBeat recorded 4 mentions for Brainstorm Cell Therapeutics and 1 mentions for Qualigen Therapeutics. Brainstorm Cell Therapeutics' average media sentiment score of 0.00 equaled Qualigen Therapeutics'average media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Brainstorm Cell Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Qualigen Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Brainstorm Cell Therapeutics is trading at a lower price-to-earnings ratio than Qualigen Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Brainstorm Cell Therapeutics	N/A	N/A	-$11.62M	-$1.64	N/A
Qualigen Therapeutics	N/A	N/A	-$6.26M	-$7.50	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Brainstorm Cell Therapeutics	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Qualigen Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Brainstorm Cell Therapeutics beats Qualigen Therapeutics on 5 of the 9 factors compared between the two stocks.

How does Qualigen Therapeutics compare to ObsEva?

ObsEva (NASDAQ:OBSV) and Qualigen Therapeutics (NASDAQ:QLGN) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, earnings, analyst recommendations, institutional ownership, risk, media sentiment, profitability and valuation.

17.5% of ObsEva shares are owned by institutional investors. Comparatively, 3.2% of Qualigen Therapeutics shares are owned by institutional investors. 14.4% of ObsEva shares are owned by company insiders. Comparatively, 1.8% of Qualigen Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Qualigen Therapeutics' return on equity of 0.00% beat ObsEva's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ObsEva	N/A	-416.36%	-92.01%
Qualigen Therapeutics	N/A	N/A	-202.16%

In the previous week, Qualigen Therapeutics had 1 more articles in the media than ObsEva. MarketBeat recorded 1 mentions for Qualigen Therapeutics and 0 mentions for ObsEva. ObsEva's average media sentiment score of 0.00 equaled Qualigen Therapeutics'average media sentiment score.

Company	Overall Sentiment
ObsEva	Neutral
Qualigen Therapeutics	Neutral

Qualigen Therapeutics is trading at a lower price-to-earnings ratio than ObsEva, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ObsEva	N/A	N/A	-$58.38M	-$0.92	N/A
Qualigen Therapeutics	N/A	N/A	-$6.26M	-$7.50	N/A

Given ObsEva's higher probable upside, analysts clearly believe ObsEva is more favorable than Qualigen Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ObsEva	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Qualigen Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

ObsEva has a beta of 0.68, meaning that its stock price is 32% less volatile than the broader market. Comparatively, Qualigen Therapeutics has a beta of 0.24, meaning that its stock price is 76% less volatile than the broader market.

Summary

ObsEva beats Qualigen Therapeutics on 7 of the 11 factors compared between the two stocks.

Get Qualigen Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding QLGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

QLGN vs. The Competition

Export

Metric	Qualigen Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$2.15M	$3.02B	$6.41B	$12.59B
Dividend Yield	N/A	1.97%	2.75%	5.26%
P/E Ratio	-0.17	17.49	21.26	26.28
Price / Sales	N/A	342.15	561.47	114.49
Price / Cash	N/A	56.31	43.49	56.90
Price / Book	-0.31	6.32	10.60	7.34
Net Income	-$6.26M	$75.84M	$3.56B	$336.95M
7 Day Performance	-1.55%	3.31%	2.82%	3.39%
1 Month Performance	-14.19%	2.11%	6.15%	7.17%
1 Year Performance	-67.01%	32.76%	36.83%	37.87%

Qualigen Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
QLGN Qualigen Therapeutics	0.0099 of 5 stars	$1.27 -0.8%	N/A	-66.3%	$2.15M	N/A	N/A	50	News Coverage
NCNA NuCana	1.0086 of 5 stars	$2.04 +3.0%	N/A	-69.7%	$8.24M	N/A	N/A	30	Positive News
MTEX Mannatech	1.3004 of 5 stars	$3.95 -6.2%	N/A	-40.7%	$8.12M	$108.04M	N/A	250	News Coverage Analyst Upgrade Short Interest Increase Gap Down
CELZ Creative Medical Technology	1.3773 of 5 stars	$2.27 +3.7%	N/A	+14.7%	$8.10M	$10K	N/A	5
BCLI Brainstorm Cell Therapeutics	0.1094 of 5 stars	$0.72 +0.8%	N/A	-32.4%	$7.95M	N/A	N/A	40	News Coverage Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:QLGN) was last updated on 5/29/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Qualigen Therapeutics (QLGN) Competitors

QLGN vs. NCNA, MTEX, CELZ, BCLI, and OBSV

How does Qualigen Therapeutics compare to NuCana?

Summary

How does Qualigen Therapeutics compare to Mannatech?

Summary

How does Qualigen Therapeutics compare to Creative Medical Technology?

Summary

How does Qualigen Therapeutics compare to Brainstorm Cell Therapeutics?

Summary

How does Qualigen Therapeutics compare to ObsEva?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

QLGN vs. The Competition

Qualigen Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Qualigen Therapeutics (QLGN) Competitors

QLGN vs. NCNA, MTEX, CELZ, BCLI, and OBSV

How does Qualigen Therapeutics compare to NuCana?

Does the media refer more to NCNA or QLGN?

Which has more risk & volatility, NCNA or QLGN?

Which has better valuation and earnings, NCNA or QLGN?

Do insiders & institutionals hold more shares of NCNA or QLGN?

Do analysts recommend NCNA or QLGN?

Is NCNA or QLGN more profitable?

Summary

How does Qualigen Therapeutics compare to Mannatech?

Is QLGN or MTEX more profitable?

Do analysts prefer QLGN or MTEX?

Does the media refer more to QLGN or MTEX?

Do insiders and institutionals hold more shares of QLGN or MTEX?

Which has more volatility and risk, QLGN or MTEX?

Which has preferable valuation and earnings, QLGN or MTEX?

Summary

How does Qualigen Therapeutics compare to Creative Medical Technology?

Does the media refer more to QLGN or CELZ?

Which has more risk & volatility, QLGN or CELZ?

Do analysts rate QLGN or CELZ?

Do institutionals & insiders hold more shares of QLGN or CELZ?

Which has better valuation & earnings, QLGN or CELZ?

Is QLGN or CELZ more profitable?

Summary

How does Qualigen Therapeutics compare to Brainstorm Cell Therapeutics?

Do insiders & institutionals hold more shares of BCLI or QLGN?

Which has more volatility & risk, BCLI or QLGN?

Is BCLI or QLGN more profitable?

Does the media prefer BCLI or QLGN?

Which has stronger valuation and earnings, BCLI or QLGN?

Do analysts rate BCLI or QLGN?

Summary

How does Qualigen Therapeutics compare to ObsEva?

Do insiders and institutionals have more ownership in OBSV or QLGN?

Is OBSV or QLGN more profitable?

Does the media prefer OBSV or QLGN?

Which has stronger valuation & earnings, OBSV or QLGN?

Do analysts prefer OBSV or QLGN?

Which has more volatility & risk, OBSV or QLGN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

QLGN vs. The Competition

Qualigen Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools